Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2016

01.01.2016 | Original Article

Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [11C]ABP688 PET

verfasst von: Jonathan M. DuBois, Olivier G. Rousset, Jared Rowley, Manuel Porras-Betancourt, Andrew J. Reader, Aurelie Labbe, Gassan Massarweh, Jean-Paul Soucy, Pedro Rosa-Neto, Eliane Kobayashi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Metabotropic glutamate receptor type 5 (mGluR5) is a G protein-coupled receptor that has been implicated in several psychiatric and neurological diseases. The radiopharmaceutical [11C]ABP688 allows for in vivo quantification of mGluR5 availability using positron emission tomography (PET). In this study, we aimed to detail the regional distribution of [11C]ABP688 binding potential (BPND) and the existence of age/sex effects in healthy individuals.

Methods

Thirty-one healthy individuals aged 20 to 77 years (men, n = 18, 45.3 ± 18.2 years; females, n = 13, 41.5 ± 19.6 years) underwent imaging with [11C]ABP688 using the high-resolution research tomograph (HRRT). We developed an advanced partial volume correction (PVC) method using surface-based analysis in order to accurately estimate the regional variation of radioactivity. BPND was calculated using the simplified reference tissue model, with the cerebellum as the reference region. Surface-based and volume-based analyses were performed for 39 cortical and subcortical regions of interest per hemisphere.

Results

We found the highest [11C]ABP688 BPND in the lateral prefrontal and anterior cingulate cortices. The lowest [11C]ABP688 BPND was observed in the pre- and post-central gyri as well as the occipital lobes and the thalami. No sex effect was observed. Associations between age and [11C]ABP688 BPND without PVC were observed in the right amygdala and left putamen, but were not significant after multiple comparisons correction.

Conclusions

The present results highlight complexities underlying brain adaptations during the aging process, and support the notion that certain aspects of neurotransmission remain stable during the adult life span.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Rev. 1999;29(1):83–120.CrossRefPubMed
2.
Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem. 2000;75(3):889–907.CrossRefPubMed
3.
Hermans E, Challiss RA. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem J. 2001;359(Pt 3):465–84.PubMedCentralCrossRefPubMed
4.
5.
Benarroch EE. Metabotropic glutamate receptors: synaptic modulators and therapeutic targets for neurologic disease. Neurology. 2008;70(12):964–8.CrossRefPubMed
6.
Ametamey SM. Radiosynthesis and Preclinical Evaluation of 11C-ABP688 as a Probe for Imaging the Metabotropic Glutamate Receptor Subtype 5. J Nucl Med. 2006;47(4):698–705.PubMed
7.
Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, et al. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med. 2007;48(2):247–52.PubMed
8.
Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U, et al. Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med. 2007;48(7):1207–15.CrossRefPubMed
9.
Hu Y, Xu Q, Li K, Zhu H, Qi R, Zhang Z, et al. Gender differences of brain glucose metabolic networks revealed by FDG-PET: evidence from a large cohort of 400 young adults. PLoS One. 2013;8(12), e83821.PubMedCentralCrossRefPubMed
10.
Madsen K, Haahr MT, Marner L, Keller SH, Baare WF, Svarer C, et al. Age and sex effects on 5-HT(4) receptors in the human brain: a [(11)C]SB207145 PET study. J Cereb Blood Flow Metab. 2011;31(6):1475–81.PubMedCentralCrossRefPubMed
11.
Grove-Strawser D, Boulware MI, Mermelstein PG. Membrane estrogen receptors activate the metabotropic glutamate receptors mGluR5 and mGluR3 to bidirectionally regulate CREB phosphorylation in female rat striatal neurons. Neuroscience. 2010;170(4):1045–55.PubMedCentralCrossRefPubMed
12.
Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry. 2011;168(7):727–34.PubMedCentralCrossRefPubMed
13.
Hulka LM, Treyer V, Scheidegger M, Preller KH, Vonmoos M, Baumgartner MR, et al. Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans. Mol Psychiatr. 2014;19(5):625–32.CrossRef
14.
DeLorenzo C, Kumar JS, Mann JJ, Parsey RV. In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688. J Cereb Blood Flow Metab. 2011;31(11):2169–80.PubMedCentralCrossRefPubMed
15.
Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D, et al. Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc Natl Acad Sci U S A. 2013;110(2):737–42.PubMedCentralCrossRefPubMed
16.
Matuskey D, Pittman B, Planeta-Wilson B, Walderhaug E, Henry S, Gallezot JD, et al. Age effects on serotonin receptor 1B as assessed by PET. J Nucl Med. 2012;53(9):1411–4.PubMedCentralCrossRefPubMed
17.
Moses-Kolko EL, Price JC, Shah N, Berga S, Sereika SM, Fisher PM, et al. Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population. Neuropsychopharmacology. 2011;36(13):2729–40.PubMedCentralCrossRefPubMed
18.
Engman J, Ahs F, Furmark T, Linnman C, Pissiota A, Appel L, et al. Age, sex and NK1 receptors in the human brain -- a positron emission tomography study with [(1)(1)C]GR205171. Eur Neuropsychopharm. 2012;22(8):562–8.CrossRef
19.
Fowler J, Volkow N, Wang G-J, Logan J, Pappas N, Shea C, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18(4):431–5.CrossRefPubMed
20.
Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol. 2012;57(21):R119–59.CrossRefPubMed
21.
Uchida H, Chow TW, Mamo DC, Kapur S, Mulsant BH, Houle S, et al. Effects of aging on 5-HT(2A) R binding: a HRRT PET study with and without partial volume corrections. Int J Geriatr Psychiatry. 2011;26(12):1300–8.CrossRefPubMed
22.
Greve DN, Svarer C, Fisher PM, Feng L, Hansen AE, Baare W, et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. NeuroImage. 2014;92:225–36.PubMedCentralCrossRefPubMed
23.
Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011;38(6):1104–19.CrossRefPubMed
24.
Elmenhorst D, Minuzzi L, Aliaga A, Rowley J, Massarweh G, Diksic M, et al. In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688. J Cereb Blood Flow Metab. 2010;30(8):1538–49.PubMedCentralCrossRefPubMed
25.
Hong I, Chung S, Kim H, Kim Y, Son Y, Cho Z. Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction. IEEE Trans Med Imaging. 2007;26(6):789–803.CrossRefPubMed
26.
Comtat C, Sureau F, Sibomana M, Hong I, Sjöholm N, Trebossen R. Image based resolution modeling for the HRRT OSEM reconstructions software. IEEE Nucl Sci Symp Conf Rec. 2008;4120–23.
27.
Sureau FC, Reader AJ, Comtat C, Leroy C, Ribeiro MJ, Buvat I, et al. Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med. 2008;49(6):1000–8.CrossRefPubMed
28.
Costes N, Dagher A, Larcher K, Evans AC, Collins DL, Reilhac A. Motion correction of multi-frame PET data in neuroreceptor mapping: simulation based validation. NeuroImage. 2009;47(4):1496–505.CrossRefPubMed
29.
Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage. 1997;6(4):279–87.CrossRefPubMed
30.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.CrossRefPubMed
31.
Milella M, Reader A, Albrechtsons D, Minuzi L, Soucy J, Benkelfat C. Human PET validation study of reference tissue models for the mGluR5 ligand [11C] ABP688. Paper presented at Society for Neuroscience Annual Meeting. Washington, DC; 2011. 946.06/AAA31.
32.
33.
Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage. 1999;9(2):179–94.CrossRefPubMed
34.
Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341–55.CrossRefPubMed
35.
Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. NeuroImage. 1999;9(2):195–207.CrossRefPubMed
36.
Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, et al. A hybrid approach to the skull stripping problem in MRI. NeuroImage. 2004;22(3):1060–75.CrossRefPubMed
37.
Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001;20(1):70–80.CrossRefPubMed
38.
Segonne F, Pacheco J, Fischl B. Geometrically accurate topology-correction of cortical surfaces using nonseparating loops. IEEE Trans Med Imaging. 2007;26(4):518–29.CrossRefPubMed
39.
Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97(20):11050–5.PubMedCentralCrossRefPubMed
40.
Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage. 2006;31(3):968–80.CrossRefPubMed
41.
42.
Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904–11.PubMed
43.
Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12(4):571–83.CrossRefPubMed
44.
Rousset O, Rahmim A, Alavi A, Zaidi H. Partial Volume Correction Strategies in PET. PET Clin. 2007;2(2):235–49.CrossRef
45.
46.
Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J R Stat Soc. 1995;57(1):289–300.
47.
48.
Tukey JW. Exploratory data analysis. Reading, MA: Addison-Wesley; 1977.
49.
Elston GN, Rockland KS. The pyramidal cell of the sensorimotor cortex of the macaque monkey: phenotypic variation. Cereb Cortex. 2002;12(10):1071–8.CrossRefPubMed
50.
Elston GN. Cortical heterogeneity: implications for visual processing and polysensory integration. J Neurocytol. 2002;31(3–5):317–35.CrossRefPubMed
51.
Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol. 2010;50:295–322.CrossRef
52.
Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol. 1995;355(3):455–69.CrossRefPubMed
53.
Hadel S, Wirth C, Rapp M, Gallinat J, Schubert F. Effects of age and sex on the concentrations of glutamate and glutamine in the human brain. JMRI-J Magn Reson Imaging. 2013;38(6):1480–7.CrossRef
54.
Sailasuta N, Ernst T, Chang L. Regional variations and the effects of age and gender on glutamate concentrations in the human brain. Magn Reson Imaging. 2008;26(5):667–75.PubMedCentralCrossRefPubMed
55.
Tsamis KI, Mytilinaios DG, Njau SN, Baloyannis SJ. Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease. Curr Alzheimer Res. 2013;10(5):469–75.CrossRefPubMed
56.
Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, et al. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy–implications for excitotoxicity. PLoS One. 2010;5(11), e14020.PubMedCentralCrossRefPubMed
57.
Notenboom RG, Hampson DR, Jansen GH, van Rijen PC, van Veelen CW, van Nieuwenhuizen O, et al. Up-regulation of hippocampal metabotropic glutamate receptor 5 in temporal lobe epilepsy patients. Brain. 2006;129(Pt 1):96–107.PubMed
58.
Menard C, Quirion R. Successful cognitive aging in rats: a role for mGluR5 glutamate receptors, homer 1 proteins and downstream signaling pathways. PLoS One. 2012;7(1), e28666.PubMedCentralCrossRefPubMed
59.
Car H, Stefaniuk R, Wiśniewska R. Effect of MPEP in Morris water maze in adult and old rats. Pharmacol Rep. 2006;59(1):88–93.
60.
Leuzy A, Zimmer ER, Dubois J, Pruessner J, Cooperman C, Soucy JP, et al. In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. Brain Struct Funct. 2015. doi:10.​1007/​s00429-014-0978-3.
61.
Rousset OG, Collins DL, Rahmim A, Wong DF. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med. 2008;49(7):1097–106.PubMedCentralCrossRefPubMed
62.
Kagedal M, Cselenyi Z, Nyberg S, Raboisson P, Stahle L, Stenkrona P, et al. A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region. NeuroImage. 2013;82:160–9.CrossRefPubMed
63.
DeLorenzo C, Milak MS, Brennan KG, Kumar JS, Mann JJ, Parsey RV. In vivo positron emission tomography imaging with [(1)(1)C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. Eur J Nucl Med Mol Imaging. 2011;38(6):1083–94.PubMedCentralCrossRefPubMed
64.
Mathews WB, Kuwabara H, Stansfield K, Valentine H, Alexander M, Kumar A, et al. Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11C] ABP688 PET imaging. Synapse. 2014;68(12):565–73.
65.
Daggett L, Sacaan A, Akong M, Rao S, Hess S, Liaw C, et al. Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5. Neuropharmacology. 1995;34(8):871–86.CrossRefPubMed
66.
Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl Med Biol. 2007;34(8):1009–17.CrossRefPubMed
67.
DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, et al. In vivo ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptors subtype 5. Biol Psychiatry. 2015;77(3):266–75.
68.
Wyckhuys T, Verhaeghe J, Wyffels L, Langlois X, Schmidt M, Stroobants S, et al. N-acetylcysteine- and MK-801-induced changes in glutamate levels do not affect in vivo binding of metabotropic glutamate 5 receptor radioligand 11C-ABP688 in rat brain. J Nucl Med. 2013;54(11):1954–61.CrossRefPubMed
69.
Zimmer ER, Parent MJ, Leuzy A, Aliaga A, Aliaga A, Moquin L, et al. Imaging in vivo glutamate fluctuations with [C]ABP688: a GLT-1 challenge with ceftriaxone. J Cereb Blood Flow Metab. 2015;35:1169–74.
Metadaten
Titel
Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [11C]ABP688 PET
verfasst von
Jonathan M. DuBois
Olivier G. Rousset
Jared Rowley
Manuel Porras-Betancourt
Andrew J. Reader
Aurelie Labbe
Gassan Massarweh
Jean-Paul Soucy
Pedro Rosa-Neto
Eliane Kobayashi
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3167-6

Weitere Artikel der Ausgabe 1/2016

European Journal of Nuclear Medicine and Molecular Imaging 1/2016 Zur Ausgabe

Original Article

Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI

Original Article

Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas

Original Article

Test–retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects

Original Article

Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride

Original Article

Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease

Erratum

Erratum to: Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis